Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 5/20 | 0.45 |
| ▸ | PPARG | P37231 | 4/20 | 0.45 |
| ▸ | CNR1 | P21554 | 1/20 | 0.42 |
| ▸ | CNR2 | P34972 | 1/20 | 0.42 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.41 |
| ▸ | PTGIR | P43119 | 1/20 | 0.39 |
| ▸ | TLR2 | O60603 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL144255 | 0.86 | PPARA (0.47) | PPARAPPARGCNR1CNR2EPHX2 | |
| Decanoic Acid SCHEMBL5458412 | 0.78 | SLC6A4 (0.54) | PPARAPPARGCNR1CNR2PTGIR | |
| Decanoic Acid SCHEMBL144254 | 0.76 | PPARA (0.51) | PPARAPPARGCNR1CNR2EPHX2 | |
| SCHEMBL30525732 | 0.73 | PPARA (0.56) | PPARAPPARGCNR1CNR2EPHX2 | |
| SCHEMBL7053659 | 0.71 | SLC6A4 (0.68) | CNR1 | |
| SCHEMBL6668951 | 0.70 | LMNA (0.51) | TLR2 | |
| SCHEMBL28377883 | 0.69 | LMNA (0.50) | PPARGTLR2 | |
| SCHEMBL28378709 | 0.69 | LMNA (0.50) | PPARGTLR2 | |
| SCHEMBL28887498 | 0.69 | LMNA (0.50) | PPARGTLR2 | |
| SCHEMBL28381167 | 0.69 | LMNA (0.50) | PPARGTLR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070208134-A1 | Anti-scarring drug combinations and use thereof | HUNTER WILLIAM L | 2007-09-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070208134-A1 | Anti-scarring drug combinations and use thereof | MMP1, COL2A1, COL1A1 | PPARA 411/4885PPARG 529/4885CNR1 2202/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.